论文部分内容阅读
目的:分析贝伐珠单抗致胃肠道穿孔(gastrointestinal perforation,GIP)的发生规律及特点,为安全用药提供参考。方法:检索2004年至2015年3月国内外学术期刊收载的贝伐珠单抗致GIP文献进行分析。结果:17例不良反应中,男性9例,女性8例,年龄≥65岁的老年患者7例(41.18%);17例GIP患者中,发生在前15周疗程内有13例(76.47%)。有7例采用非手术保守治疗,10例采取手术治疗,死亡7例。结论:临床医师应了解贝伐珠单抗致GIP的规律和特点,加强用药监测,以便及时发现和处理GIP。
OBJECTIVE: To analyze the occurrence and characteristics of the gastrointestinal perforation (GIP) induced by bevacizumab and to provide a reference for safe drug use. METHODS: The literature of GIP induced by bevacizumab collected from academic journals from 2004 to March 2015 was searched. Results: Of the 17 adverse reactions, 9 were male and 8 were female, and 7 (41.18%) were elderly patients aged 65 years or older. Of the 17 patients with GIP, 13 (76.47%) occurred during the first 15 weeks of treatment, . 7 cases were treated conservatively, 10 cases were treated surgically and 7 died. Conclusion: Clinicians should understand the regularity and characteristics of GIP induced by bevacizumab and strengthen the monitoring of medication in order to discover and treat GIP in time.